MRNA logo

Moderna Inc. (MRNA)

$206.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MRNA

Market cap

$83.68B

EPS

-7.09

P/E ratio

--

Price to sales

39.96

Dividend yield

--

Beta

1.162536

Price on MRNA

Previous close

$215.27

Today's open

$219.85

Day's range

$203.84 - $222.43

52 week range

$22.28 - $280.80

Profile about MRNA

CEO

Stéphane Bancel

Employees

4700

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

404620975

Issue type

Common Stock

MRNA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MRNA

Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity

Moderna NASDAQ: MRNA is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data.

news source

MarketBeat • 11 hours ago

news preview

Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 11 hours ago

news preview

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.

news source

Zacks Investment Research • 8 hours ago

news preview

Is Moderna's Cancer Vaccine a Game Changer for the Stock?

Intismeran and Keytruda have demonstrated in clinical trials that they can drastically improve outcomes for melanoma patients. The combined treatment has reduced the risk of death and melanoma spreading or returning.

news source

The Motley Fool • Nov 16, 2026

news preview

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

Axsome Therapeutics is experiencing rapid revenue growth driven by its portfolio of central nervous system treatments. Moderna is diversifying its messenger RNA platform into respiratory vaccines and oncology while facing significant net losses.

news source

The Motley Fool • Nov 14, 2026

news preview

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Why Moderna Stock Dropped on Thursday

Moderna's revenue guidance for 2026 falls short of analyst targets, meaning a sales miss may be coming. Moderna's earnings might surprise to the upside if its cost-cutting pays off.

news source

The Motley Fool • Nov 12, 2026

news preview

Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook

Moderna NASDAQ: MRNA is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck if regulators approve the therapy.

news source

MarketBeat • Nov 12, 2026

news preview

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.

news source

Market Watch • Nov 12, 2026

news preview

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?

Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.

news source

Zacks Investment Research • Nov 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Moderna Inc.

Open an M1 investment account to buy and sell Moderna Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MRNA on M1